2. Signaling Pathways
  3. Cytoskeleton
  4. Myosin
  5. Myosin Isoform
  6. Myosin Inhibitor

Myosin Inhibitor

Myosin Inhibitors (58):

Cat. No. Product Name Effect Purity
  • HY-13441
    (-)-Blebbistatin
    		Inhibitor 98.68%
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
  • HY-13813
    Blebbistatin
    		Inhibitor 99.64%
    Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration.
  • HY-100912
    W-7 hydrochloride
    		Inhibitor 99.96%
    W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias.
  • HY-17681
    Myosin-IN-5
    		Inhibitor
    Myosin-IN-5 (example 3) is a selective cardiac myosin inhibitor with an IC50 of 1.5 μM. Myosin-IN-5 shows much less effective in inhibiting skeletal myofibril activity (IC50 of 43.4 μM). Myosin-IN-5 can be used for the study of hypertrophic cardiomyopathy (HCM) and cardiac diseases.
  • HY-180792
    CK-571
    		Inhibitor
    CK-571 is a potent and selective inhibitor of smooth muscle myosin-2 (SMM), with an IC50 value of 86 nM. CK-571 exhibits IC50 values for cardiac muscle myosin (CMM), skeletal muscle myosin (SKM), and non-muscle myosin-2A (NMM-2A) of 2.3, 42, and 0.58 μM, respectively. CK-571 can be used for research on asthma, chronic obstructive pulmonary disease, and other smooth muscle-related diseases.
  • HY-139465
    Aficamten
    		Inhibitor 99.86%
    Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).
  • HY-120870
    para-Nitroblebbistatin
    		Inhibitor 99.0%
    para-Nitroblebbistatin is a derivative of Blebbistatin (HY-13813) and an inhibitor of myosin II. para-Nitroblebbistatin is photostable, non-cytotoxic, and non-phototoxic. para-Nitroblebbistatin can serve as an ideal substitute for Blebbistatin (HY-13813) to study the role of myosin II in physiology, development, and cell biology.
  • HY-Y0413
    Biacetyl monoxime
    		Inhibitor 98.0%
    Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release.
  • HY-148799
    Sevasemten
    		Inhibitor 99.32%
    Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models.
  • HY-100932
    ML-9
    		Inhibitor 99.86%
    ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
  • HY-16690
    BTS
    		Inhibitor 99.79%
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers.
  • HY-111474
    Para-aminoblebbistatin
    		Inhibitor 99.90%
    Para-aminoblebbistatin is the inhibitor for myosin II. Para-aminoblebbistatin inhibits the ATPase activity of myosin II, thereby blocking the formation and contraction of the actin-myosin network. Para-aminoblebbistatin is a non-fluorescent and photostable Blebbistatin (HY-13813) derivative.
  • HY-148516
    MPH-220
    		Inhibitor 99.25%
    MPH-220 is a selective and orally active inhibitor of skeletal muscle myosin-2. MPH-220 enables muscle relaxation. MPH-220 is anti-spastic agent that can be used in the research of spasticity and muscle stiffness.
  • HY-163084
    HJ445A
    		Inhibitor 98.02%
    HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a KD of 0.17 μM. HJ445A potently repressed the proliferation of gastric cancer cells with IC50 values of 0.16 and 0.14 μM in MGC803 and MKN45, respectively. HJ445A demonstrates superior antitumor efficacy in vivo and can be used for cancer research.
  • HY-107657
    (+)-Blebbistatin
    		Inhibitor 98.17%
    (+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective inhibitor of myosin II ATPase.
  • HY-152949
    Myosin V-IN-1
    		Inhibitor
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex.
  • HY-115669
    Pentachloropseudilin
    		Inhibitor 98.88%
    Pentachloropseudilin (Antibiotic A 15104 Y; PClP) is a reversible and allosteric potent inhibitor of Myo1s (class 1 myosins) with IC50s range from 1 to 5 μM for mammalian class-1 myosins and greater than 90 μM for class-2 and class-5 myosins. Pentachloropseudilin is a potent inhibitor of transforming growth factor-β (TGF-β)-stimulated signaling, with an IC50 of 0.1 to 0.2 μM for TGF-β.
  • HY-175199
    MT-228
    		Inhibitor 99.9%
    MT-228 (BPN-0026709) is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder.
  • HY-168529
    NU074381b
    		Inhibitor 98.54%
    NU074381b (compound 5b) is a potent S100A4 inhibitor. NU074381b inhibits S100A4-NMII complex formation with an IC50 value of 0.48 µM. NU074381b inhibits cell proliferation and migration.
  • HY-175188
    MT-110
    		Inhibitor 99.48%
    MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder.